Low density lipoprotein oxidation and atherogenesis: From experimental models to clinical studies

Giornale Italiano di Cardiologia

Volumn 27, Issue 12, 1997, Pages 1302-1314

  Napoli, Claudio ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE   (Italy)

Author keywords

Antioxidants; Oxidation

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA CAROTENE; CALCIUM CHANNEL BLOCKING AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; NIFEDIPINE; PROBUCOL; RETINOL;

AGED; ANIMAL MODEL; ATHEROGENESIS; ATHEROSCLEROSIS; CLINICAL TRIAL; EXPERIMENTAL MODEL; FEMALE; FETUS; HUMAN; IMMUNE RESPONSE; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; NONHUMAN; REVIEW;

ANIMALS; ANTIBODY FORMATION; ANTIOXIDANTS; AORTA; ARTERIOSCLEROSIS; CARDIOVASCULAR AGENTS; EPITOPES; HUMANS; IMMUNITY, CELLULAR; LIPOPROTEINS, LDL; OXIDATION-REDUCTION;

EID: 0031443571     PISSN: 00465968     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. CONSENSUS CONFERENCE: Lowering blood cholesterol to prevent coronary heart disease. JAMA 1985; 253: 2080-2090.
2. EUROPEAN ATHEROSCLEROSIS SOCIETY STUDY GROUP: Strategies for the prevention of coronary heart disease. Eur Heart J 1987; 8: 77-88.
3. STEINBERG D: The cholesterol controversy is over. Why did it take so long? Circulation 1989; 80: 1070-1078.
4. PEDERSON TR, KJEKHUS J, BERG K, ET AL: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
5. WITZTUM JL, STEINBERG D: Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 1991; 88: 1785-1792.
6. BERLINER JA, NAVAB M, FOGELMAN AM, ET AL: Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
7. BERLINER JA, HEINECKE JW: The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996; 20: 707-727.
8. NAPOLI C, SCARPATO N, POSTIGLIONE A: Danno ossidativo e lipoproteine a bassa densitá (LDL) nella aterogenesi. In: SCARPATO N (ed): Artti del VII Congresso Nazionale della Società Italiana di Emaferesi, 1995. Napoli, Ariello Editori, 1996; 25-37.
9. PALINSKI W, WITZTUM JL: Oxidative stress and diabetes mellitus. In: BORN GVR, SCHWARTZ CD (eds): New horizons in diabetes mellitus and coronary heart disease. London, Current Science, 1995; 111-123.
10. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-808.
11. POSTIGLIONE A, NAPOLI C: Hyperlipidaemia and atherosclerotic cerebrovascular disease. Curr Opin Lipidol 1995; 6: 236-242.
12. POSTIGLIONE A, NAPOLI C, D'ARMIENTO FP, RUOCCO A, DI MINNO G: Plasma lipids, lipoproteins and atherosclerosis of cerebral vessels. Nutr Metab Cardiovasc Dis 1997; 7: 231-236.
13. BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-38.
14. KODAMA T, FREEMAN M, ROHRER L, ZABRECKY T, MATSUDAIRA P, KRIEGER M: Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990; 343: 531-535.
15. RAMPRASAD M, FISCHER W, WITZTUM JL, SAMBRANO G, QUEHENBERGER O, STEINBERG D: The 94-96 kDa mouse macrophage membrane protein that recognizes oxidized low density lipoprotein and phosphatidylserine-rich liposomes is identical to macrosialin, the mouse homologue of human CD68. Proc Natl Acad Sci USA 1995; 92: 9580-9584.
16. FREEMAN M, ASHKENAS J, REES DJ, ET AL: An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors. Proc Natl Acad Sci USA 1990; 87: 8810-8814.
17. QUINN MT, PARTHASARATHY S, FONG LG, STEINBERG D: Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 1987; 84: 2995-2998.
18. QUINN MT, PARTHASARATHY S, STEINBERG D: Lysophosphatidylcholine: a new chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci USA 1988; 85: 2805-2809.
19. HABERLAND ME, FONG D, CHENG L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988; 241: 215-218.
20. PALINSKI W, ROSENFELD ME, YLÄ-HERTTUALA S, ET AL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 1989; 86: 1372-1376.
21. YLÄ-HERTTUALA S, PALINSKI W, ROSENFELD ME, ET AL: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-1095.
22. BOYD HC, GOWN AM, WOLFBAUER G, CHAIT A: Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a Watanabe heritable hyperlipidemic rabbit. Am J Pathol 1989; 135: 815-826.
23. ROSENFELD ME, PALINSKI W, YLÄ-HERTTUALA S, BUTLER S, WITZTUM JL: Distribution of oxidation-specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990; 19: 336-349.
24. JÜRGENS G, CHEN Q, ESTERBAUER H, MAIR S, LEDINSKI G, DINGES HP: Immunostaining of human autopsy aortas with antibodies to modified apolipoprotein B und apoprotein (a). Arterioscler Thromb 1993; 13: 1689-1699.
25. PALINSKI W, ORD V, PLUMP AS, BRESLOW JL, STEINBERG D, WITZTUM JL: ApoE deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehydelysine in serum. Arterioscler Thromb 1994; 14: 605-616.
26. PALINSKI W, TANGIRALA RK, MILLER E, YOUNG SG, WITZTUM JL: Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1569-1576.
27. CAREW TE, SCHWENKE DC, STEINBERG D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks slowing the progression of atherosclerosis in the WHHL rabbit. Proc Natl Acad Sci USA 1987; 84: 7725-7729.
28. BJÖRKHEM I, HENRIKSSON-FREYSCHUSS A, BREUER O, DICZFALUSY U, BERGLUND L, HENRIKSSON P: The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 1991; 11: 15-22.
29. SPARROW CP, DOEBBER TW, OLSZEWSKI J, ET AL: Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N″-diphenylphenylenediamine. J Clin Invest 1992; 89: 1885-1891.
30. SASAHARA M, RAINES EW, CHAIT A, ET AL: Inhibition of hypercholesterolemia-induced atherosclerosis in Macaca Nemestrina by probucol. I. Intimal lesion area correlates inversely with resistance of lipoproteins to oxidation. J Clin Invest 1994; 94: 155-164.
31. TANGIRALA RK, CASANADA F, WITZTUM JL, STEINBERG D, PALINSKI W: Effect of the antioxidant N,N′-diphenyl, 1,4-phenylenediamine (DPPD) on atherogenesis in apoE-deficient mice. Arterioscler Thromb Vasc Biol 1995; 15: 1625-1630.
32. HESSLER JR, ROBERTSON AL JR, CHISOLM GM: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 1979; 32: 213-229.
33. PALINSKI W, YLÄ-HERTTUALA S, ROSENFELD ME, ET AL: Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10: 325-335.
34. KUGIYAMA K, KERNS SA, MORRISETT JD, ROBERTS R, HENRY PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low density lipoproteins. Nature 1990; 344: 160-162.
35. NAPOLI C, PATERNÒ R, FARACI FM, TAGUCHI H, POSTIGLIONE A, HEISTADD DD: Mildly oxidized low-density lipoprotein impairs responses of carotid but not basilar artery. Stroke 1997; 28: 2266-2272.
36. AVIRAM M: Modified forms of low density lipoprotein affect platelet aggregation in vitro. Thromb Res 1989; 53: 561-567.
37. FEI H, BERLINER JA, PARHAMI A, DRAKE TA: Regulation of endothelial cell tissue factor expression by minimally oxidized LDL and lipopolysaccharide. Arterioscler Thromb 1993; 13: 1711-1717.
38. CLINTON SK, LIBBY P: Cytokines and growth factors in atherogenesis. Arch Pathol Lab Med 1992; 116: 1292-1300.
39. CUSHING SD, BERLINER JA, VALENTE AJ, ET AL: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990; 87: 5134-5138.
40. RAJAVASHISTH TB, ANDALIBI A, TERRITO MC, ET AL: Induction of endothelial cell expression of granulocyte and macrophage colony stimulating factors by modified low density lipoproteins. Nature 1990; 334: 254-257.
41. LIAO F, ANDALIBI A, QIAO JH, ALLA YEE H, FOGELMAN AM, LUSIS AJ: Genetic evidence for a common pathway mediating oxidative stress, inflammatory gene induction, and aortic fatty streak formation in mice. J Clin Invest 1994; 94: 877-884.
42. LIAO F, ANDALIBI A, DEBEER FC, FOGELMAN AM, LUSIS AJ: Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993; 91: 2572-2579.
43. KUME N, CYBULSKI MI, GIMBRONE MA: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992; 90: 1138-1144.
44. MEYER M, SCHRECK R, BAEUERLE PA: H202 and antioxidants have opposite effects on activation of NF-kappa B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. Embo J 1993; 12: 2005-2015.
45. MARUI N, OFFERMANN MK, SWERLICK R, ET AL: Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 1993; 92: 1866-1874.
46. KHAN BV, PARTHASARATHY S, ALEXANDER RW, MEDFORD RM: Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 1995; 95: 1262-1270.
47. FARUQI R, DE LA MOTTE C, DICORLETO PE: Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest 1994; 94; 592-600.
48. ESTERBAUER H, SCHAUR RJ, ZOLLNER H: Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
49. STEINBRECHER UP: Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J Biol Chem 1987; 262: 3603-3608.
50. WITZTUM JL, STEINBRECHER UP, FISHER M, KESÄNIEMI A: Nonenzymatic glucosylation of homologous LDL and albumin render them immunogenic in the guinea-pig. Proc Natl Acad Sci USA 1983; 80: 2757-2761.
51. ROSENFELD ME, KHOO JC, MILLER E, PARTHASARATHY S, PALINSKI W, WITZTUM JL: Macrophage-derived foam cells freshly isolated from rabbit atherosclerotic lesions degrade modified lipoproteins, promote oxidation of LDL, and contain oxidation specific lipid-protein adducts. J Clin Invest 1991; 87: 90-99.
52. PALINSKI W, HÖRKKÖ S, MILLER E, ET AL: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apo E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98: 800-814.
53. SALONEN JT, YLÄ-HERTTUALA S, YAMAMOTO R, ET AL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
54. VIRELLA G, VIRELLA I, LEMAN RB, PRYOR MB, LOPES-VIRELLA MF: Antioxidized low density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993; 23: 95-101.
55. PUURUNEN M, MÄNTTÄRI M, MANNINEN V, ET AL: Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609.
56. BERGMARK C, WU R, DE FAIRE U, LEFVERT AK, SWEDENBORG J: Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15: 441-445.
57. MAGGI E, CHIESA R, MELISSANO G, ET AL: LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler Thromb 1994; 14: 1892-1899.
58. PALINSKI W, TANGIRALA R, MILLER E, YOUNG SG, WITZTUM JL: Increased autoantibody titers against epitopes of oxidized low density lipoprotein in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1569-1576.
59. NAPOLI C, POSTIGLIONE A, TRIGGIANI M, ET AL: Oxidative structural modifications of low density lipoproteins in homozygous familial hypercholesterolemia. Atherosclerosis 1995; 118: 259-273.
60. NAPOLI C, POSTIGLIONE A, SCARPATO N, ET AL: Modified-LDL during LDL-apheresis in homozygous hypercholesterolemia. Circulation 1995; 92 (Suppl I): 197.
61. NAPOLI C, POSTIGLIONE A, CONDORELLI M, CHIARIELLO M, MANCINI M: LDL oxidation during selective LDL-apheresis in homozygous familial hypercholesterolemia. In: GOTTO AM, PAOLETTI R (eds): Proceedings of the XIIth International Symposium on Drugs Affecting Lipid Metabolism. Houston, Baylor College of Medicine Press, 1995; 87-88.
62. NAPOLI C, POSTIGLIONE A, AMBROSIO G, CONDORELLI M, CHIARIELLO M, MANCINI M: Ossidazione delle LDL nella ipercolesterolemia familiare omozigote: effetti della terapia con LDL-aferesi. Cardiologia 1996; 41: 435-439.
63. NAPOLI C, AMRBOSIO G, SCARPATO N, ET AL: Decreased LDL oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997; 133: 585-595.
64. LIBBY P, HANSSON GK: Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
65. KHOO JC, MILLER E, PIO F, STEINBERG D, WITZTUM JL: Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992; 12: 1258-1266.
66. LOPES-VIRELLA MF, GRIFFITH RL, SHUNK KA, VIRELLA GT: Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb 1991; 11: 1356-1367.
67. JONASSON L, HOLM J, SKALLI O, GABBIANI G, HANSSON GK: Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J Clin Invest 1985; 76: 125-131.
68. XU Q, OBERHUBER G, GRUSCHWITZ M, WICK G: Immunology of atherosclerosis: cellular composition and major histocompatibility complex class II antigen expression in aortic intima, fatty streaks, and atherosclerotic plaques in young and aged human specimens. Clin Immunol Immunopathol 1990; 56: 344-359.
69. STEMME S, HOLM J, HANSSON GK: T lymphocytes in human atherosclerotic plaques are memory cells expressing CD45RO and the integrin VLA-1. Arterioscler Thromb 1992; 12: 206-211.
70. VLAICU R, NICULESCU F, RUS HG, CRISTEA A: Immunohistochemical localization of the terminal C5b-9 complement complex in human aortic fibrous plaque. Atherosclerosis 1985; 7: 163-177.
71. XU Q, DIETRICH H, STEINER HJ, ET AL: Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler Thromb 1992; 12: 789-799.
72. PALINSKI W, MILLER E, WITZTUM JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995; 92: 821-825.
73. AMELI S, HULTGÅRDTH-NILSSON A, REGNSTRÖM J, ET AL: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
74. HANSSON GK, HOLM J, HOLM S, FOTEV Z, HEDRIC HJ, FINGERLE J: T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA 1991; 88: 10530-10534.
75. ROSELAAR SE, SCHONFELD G, DAUGHERTY A: Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest 1995; 96: 1389-1394.
76. FYFE AI, QIAO JH, LUSIS AJ: Immune deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest 1994; 94: 2516-2520.
77. THOMAS CE, JACKSON RC: Lipid hydroperoxide involvement in copper-dependent and independent oxidation of low density lipoprotein. J Pharmacol Exp Ther 1991; 256: 1182-1186.
78. MAY PM, LINDER PW, WILLIAMS DR: Computer stimulation of metal-ion equilibria in biofluids: models for the low-molecular-weight complex distribution of calcium, magnesium, manganese, iron, copper, zinc, and lead ions in blood plasma. J Chem Soc Dalton Trans 1977; 542: 588-595.
79. NAPOLI C, TRIGGIANI M, PALUMBO G, ET AL: Glycosylation enhances oxidation and decreases acetylhydrolase activity of human low density lipoprotein. Basic Res Cardiol 1997; 92: 96-105.
80. AMBROSIO G, NAPOLI C, ORIENTE A, ET AL: Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet activating factor. J Clin Invest 1994; 93: 2408-2416.
81. SCHEEK LM, WISEMAN SA, TIJBURG LBM, VAN TOL A: Dialysis of isolated low density lipoprotein induces a loss of lipophilic antioxidants and increases the susceptibility to oxidation in vitro. Atherosclerosis 1995; 117: 139-144.
82. NAPOLI C, MANCINI FP, CORSO G, ET AL: A simple and rapid purification procedure minimizes spontaneous oxidative modifications of low density lipoprotein and lipoprotein (a). J Biochemistry 1997; 121: 1096-1101.
83. NAPOLI C: LDL oxidation and variant angina: role of methodological procedures in LDL oxidizability assessment. J Am Coll Cardiol 1996; 28: 1637-1638.
84. 1H-Nuclear magnetic resonance analysis. Clin Chim Acta 1997; 258: 193-200.
85. CHAPMAN MJ, HUBY T, NIGON F, THILLET J: Lipoprotein (a): implication in atherothrombosis. Atherosclerosis 1994; 110: S69-S75.
86. UTERMANN G, SCRIVER CR, BEAUDET AC, SLY WS, VALLE D (eds): Lipoprotein (a): the metabolic basis of inherited diseases. New York, Mc Graw Hill Inc, 1995; 1887-1912.
87. LIU CA, LAWN RM: Vascular interactions of lipoprotein (a). Curr Opin Lipidol 1994; 5: 269-273.
88. NARUSZEWICZ M, SELINGER E, DAVIGNON J: Oxidative modification of lipoprotein (a) and the effect of β-carotene. Metabolism 1992; 41: 1215-1224.
89. NAPOLI C, MANCINI FP, D'ARMIENTO FP, ET AL: Effects of oxygen radicals on human lipoprotein (a) and low density lipoprotein peroxidation and metabolism. J Am Coll Cardiol 1997; 29 (Suppl A): 160.
90. NAPOLI C, D'ARMIENTO FP, MANCINI FP, TUFANO A, CALÌ A, POSTIGLIONE A: Removal of mild oxidized lipoprotein (a) by rat hepatic Kupffer cells. Council of arteriosclerosis. Circulation 1996; 94 (Suppl II): 104.
91. MIWA K, MIYAGI Y, FUJITA M: Susceptibility of plasma low density lipoprotein to cupric ion-induced peroxidation in patients with variant angina. J Am Coll Cardiol 1995; 26: 632-638.
92. NAPOLI C, LEPORE S, SCOGNAMIGLIO A, ONORATI A, CONDORELLI M, AMBROSIO G: LDL oxidation in patients with type-1 (insulin-dependent) diabetes: correlation with glycemic control. Circulation 1995; 92 (Suppl I): 343.
93. SCARPATO N, NAPOLI C, POSTIGLIONE A, ET AL: Modifica strutturale delle lipoproteine a bassa densità nella aterogenesi della ipercolesterolemia familiare omozigote: effetti della terapia con LDL-aferesi. In: RICCI G (ed): L'aferesi terapeutica: necessità di ricerca finalizzata. CNR-Progetto Finalizzato FATMA 1995; 105-110.
94. SCARPATO N, NAPOLI C, POSTIGLIONE A, FORMISANO S, POSTIGLIONE A, MANCINI M: LDL-aferesi selettiva: nuove prospettive di ricerca. In: SCARPATO N (ed): Atti del VII Congresso Nazionale della Società Italiana di Emaferesi, 1995. Napoli, Ariello Editori, 1996; 103-109.
95. GORDON BR, SAAL SD: Advances in LDL-apheresis for the treatment of severe hypercholesterolemia. Curr Opin Lipidol 1994; 5: 69-75.
96. TATAMI R, INOUE N, ITOH H, ET AL: Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. Atherosclerosis 1992; 95: 1-13.
97. SEIDEL D, ARMSTRONG VW, SCHUFF-WERNER P: The HELP-LDL Apheresis Multicenter Study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. Evaluation of a safety and cholesterol-lowering effects during the first 12 months. Eur J Clin Invest 1991; 21: 375-383.
98. SIMONS L, REICHL D, MYANT NB, MANCINI M: The metabolism of apoprotein of plasma low density lipoprotein in familial hyperbetalipoproteinemia in the homozygous form. Atherosclerosis 1975; 21: 283-289.
99. NAPOLI C, ABETE P, CORSO G, ET AL: Increased low-density lipoprotein peroxidation in elderly men. Coronary Artery Dis 1997; 8: 129-136.
100. REGNSTRÖM J, NILSSON J, TORNVALL P, LANDOU C, HAMSTEN A: Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 1992; 339: 1183-1186.
101. COMINACINI L, GARBIN U, PASTORINO AM, ET AL: Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 1993; 99: 63-70.
102. CHAIT A, BRAZG RL, TRIBBLE DL, KRAUSS RM: Susceptibility of small, dense, low-density lipoproteins to oxidative modifications in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 1993; 94: 350-356.
103. MAGGI E, MARCHESI E, RAVETTA V, FALASCHI F, FINARDI G, BELLOMO G: Low density lipoprotein oxidation in esential hypertension. J Hypertens 1993; 11: 1103-1111.
104. GETZ GS, VESSELINOVITICH D, WISSLER RW: A dynamic pathology of atherosclerosis. Am J Med 1969; 46: 657-664.
105. PEARSON PA, KRAMER EC, SOLEZ K, HEPTINSTALL RH: The human atherosclerotic plaque. Am J Pathol 1977; 86: 657-664.
106. D'ARMIENTO FP, DI GREGORIO F, NAPOLI C, ET AL: Histological findings and evidence of lipid conjugated dienes and malondialdehyde in human fetal aortas. Acta Paediatrica 1993; 82: 823-828.
107. HELMER ME, COOK HW, LANDS WEM: Prostaglandin biosynthesis can be triggered by lipid peroxides. Arch Biochem Biophys 1979; 193: 340-345.
108. CAPDEVILLA J, MARNETT LJ, CHACOS N, PROUGH RA, ESTABROOK RW: Cytochrome P450-dependent oxygenation of arachidonic acid to hydroxyicosatetranoic acids. Proc Natl Acad Sci USA 1982; 79: 767-770.
109. NAPOLI C, D'ARMIENTO FP, MANCINI FP, WITZTUM JL, PALUMBO G, PALINSKI W: Maternal hypercholesterolemia induces early atherosclerotic lesions containing oxidation-specific epitopes in human fetal aortas. J Clin Invest 1997, in press.
110. FRUEBIS J, CAREW TE, PALINSKI W: Effect of vitamin E on atherogenesis in LDL receptor-deficient rabbits. Atherosclerosis 1995; 117: 217-224.
111. FRUEBIS J, STEINBERG D, DRESEL HA, CAREW TE: A comparison of the antiatherogenic effects of probucol and of a structural analog of probucol in LDL-receptor-deficient rabbits. J Clin Invest 1994; 94: 392-398.
112. STEINBERG D: Antioxidants and atherosclerosis. Circulation 1992; 84: 1420-1427.
113. STEINBERG D: Antioxidants, vitamins and coronary heart disease. N Engl J Med 1993; 328: 1487-1489.
114. JHA P, FLATHER M, LONN E, FARKOUH M, YASUF S: The antioxidant vitamins and cardiovascular disease. A critical review of epidemiological and clinical trial data. Ann Intern Med 1995; 123: 860-872.
115. ALPHA-TOCOPHEROL, BETA-CAROTENE CANCER PREVENTION STUDY GROUP: The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-1035.
116. WALLDIUS G, ERIKSSON U, OLSSON AG, ET AL: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994; 74; 875-883.
117. GAZIANO MJ, MANSON JE, HENNEKENS CH: Natural antioxidants and cardiovascular disease: observational epidemiologic studies and randomized trials. In: FREI B (ed): Natural antioxidants in human health. San Diego, Academic Press, 1994; 387-409.
118. BLOT WJ, LI JY, TAYLOR PR, ET AL: Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer I 1993; 85: 1483-1492.
119. OMENN GS, GOODMAN GE, THORNQUIST MD, ET AL: Effects of a combination of beta-carotene and vitamin E on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-1155.
120. HENNEKENS CH, BURING JE, MANSON JE, ET AL: Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
121. STEPHENS NG, PARSONS A, SCHONFELD PM, ET AL: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-786.
122. MANSON JE, GAZIANO JM, SPELSBERG A, ET AL: A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women: rationale's design and methods. Ann Epidemio 1995; 5: 261-268.
123. THE HOPE (HEART OUTCOMES PREVENTION EVALUATION) STUDY INVESTIGATORS: The design of a large, simple, randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12: 127-137.
124. HODIS HN, MACK WJ, LA BREE L, ET AL: Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. JAMA 1995; 278: 1849-1854.
125. KRITCHEVSKY SB, SHIMAKAWA T, TELL GS, ET AL: Dietary antioxidants and carotid artery wall thickness. The ARIC (Atherosclerosis Risk In Communities) Study. Circulation 1995; 92: 2142-2150.
126. AZEN SPO, QIAN D, MACK WJ, ET AL: Effect of supplementary antioxidant vitamin intake on carotid arterial wall intima-media thickness in a controlled clinical trial of cholesterol lowering. Circulation 1996; 94: 2369-2372.
127. HEITZER T, JUST H, MUNZEL T: Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996; 94: 6-9.
128. RICE-EVANS C, DIPLOCK AT: Current status of antioxidant therapy. Free Radic Biol Med 1993; 15: 77-96.
129. NAPOLI C, PALUMBO G, CHIARIELLO P, ET AL: Protection by β-blocking agents against oxygen radical-induced human low density lipoprotein peroxidation. J Am Coll Cardiol 1994; 23 (Suppl A): 482.
130. NAPOLI C, AMBROSIO G, CHIARIELLO P, ET AL: Protezione da parte del β-bloccanti della perossidazione delle lipoproteine umane a bassa densità indotta dai radicali liberi dell'ossigeno. G Ital Cardiol 1994; 24: 361-366.
131. NAPOLI C, AMBROSIO G, PALUMBO G, ET AL: β-blocker agents prevent oxygen radical-induced human apolipoprotein B100 oxidation. J Am Coll Cardiol 1995; 25 (Suppl A): 84.
132. NAPOLI C, CORSO G, CONDORELLI M, AMBROSIO G: Decreased cholesteryl esterification by β-blocker agents in oxidized LDL. Council of arteriosclerosis. Circulation 1996; 94 (Suppl II): 100.
133. NAPOLI C, D'ARMIENTO FP, CORSO G, ET AL: Decreased cholesteryl esterification by β-blocker agents in human oxidized low density lipoprotein. J Am Coll Cardiol 1997; 29 (Suppl A): 343.
134. NAPOLI C, AMBROSIO G, PALUMBO G, ET AL: I calcio antagonisti sono inibitori della perossidazione delle LDL umane indotta dai radicali liberi dell'ossigeno. Cardiologia 1992; 37: 49-52.
135. NAPOLI C, CHIARIELLO M, PALUMBO G, AMBROSIO G: Calcium channel blockers inhibit human low density lipoprotein oxidation by oxygen radicals. Cardiovasc Drug Ther 1996; 10: 417-424.